Matthew Hook, MD
Interventional Cardiology · Smithfield, NCNPI 1093785974
Payments from drug & device makers
What this record shows
This record is dominated by other: $11,000 of the $15,351 with a category attached, or 71.7%. Angiodynamics, Inc. accounts for 71.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $6,554 and has fallen 89.7% since, to $676 in 2025.
Across 201 payments — averaging $76.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$11K
- Boston Scientific$703
- Medtronic$698
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$679
- AstraZeneca$447
- Biotronik Inc.$415
- plus $1K from 22 others
Across 1 payment — averaging $3456.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$3K
Across 7 payments — averaging $32,955 each. An ownership or investment interest held by the physician or an immediate family member.
- Contego Medical, Inc$231K
What the payments were for
- Food & beverage$4,35128%
- Other$11,00072%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $11,000 |
| Boston Scientific | 21 | $703 |
| Medtronic(2 entities) | 20 | $698 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 59 | $679 |
| AstraZeneca | 24 | $447 |
| Biotronik Inc. | 11 | $415 |
| Abbott | 14 | $322 |
| Teleflex LLC | 8 | $165 |
| Osprey Medical Inc | 2 | $134 |
| Abiomed | 5 | $130 |
| Novartis | 7 | $122 |
| Shockwave Medical, Inc | 6 | $102 |
| Irhythm Technologies, Inc. | 2 | $69 |
| Cordis US CORP. | 2 | $49 |
| Kestra Medical Technology Services, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Biosense Webster, Inc. | 2 | $33 |
| Endotronix, Inc. | 1 | $30 |
| Johnson & Johnson | 2 | $28 |
| Baxter Healthcare | 1 | $21 |
| Novo Nordisk | 1 | $18 |
| Amgen | 1 | $18 |
| Medline Industries LP | 1 | $17 |
| Terumo Medical Corporation | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Acist Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$11,000
- HawkOne$357
- ELUVIA$143
- Acticor$122
- Solia$122
- BioMonitor$122
- Rivacor$122
- Edora$122
- DyeVert$103
How this compares
$15,351 in reported general payments places this provider in the 70th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $162,125 |
| Repatha SureclickEvolocumab | 44 | $49,683 |
| JardianceEmpagliflozin | 28 | $30,325 |
| BrilintaTicagrelor | 52 | $29,922 |
| XareltoRivaroxaban | 24 | $25,193 |
| Praluent PenAlirocumab | 25 | $17,408 |
| ClopidogrelClopidogrel Bisulfate | 675 | $6,631 |
| Ranolazine ErRanolazine | 72 | $5,808 |
| NexletolBempedoic Acid | 11 | $5,095 |
| Prasugrel Hcl | 32 | $2,779 |
| Metoprolol Succinate | 244 | $2,692 |
| Rosuvastatin Calcium | 180 | $2,550 |
| Atorvastatin Calcium | 225 | $1,784 |
| Amiodarone Hcl | 25 | $1,674 |
| Losartan Potassium | 105 | $862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $16 | $30,32528 claims |
| AstraZenecaBrilinta | $447 | $29,92252 claims |
| Johnson & JohnsonXarelto | $28 | $25,19324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Smithfield
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
- Steven FilbyPinehurst$442K
- Naveed RajperStatesville$223K
- Siddhartha RaoCary$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.